Trial reportFrontiers in nutrition2026
Orally administered scallop-derived plasmalogens improve cognitive function in healthy middle-aged and older adults: a randomized, double-blind, placebo-controlled trial.
Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasmalogens (Pls) are ether phospholipids enriched in the brain that help maintain synaptic integrity and support cognitive function. However, evidence of their cognitive benefits in otherwise healthy individuals remains limited. This randomized, double-blind, placebo-controlled trial examined whether supplementation with scallop-derived Pls (sPls) improves cognitive performance in cognitively healthy Japanese adults aged ≥40 years with below-average verbal memory at baseline. Methods: Of 168 individuals screened, 68 eligible participants were randomly assigned (1:1) to receive either sPls (1 mg/day) or placebo for 12 weeks. Cognitive performance was assessed using the web-based Cognitrax battery (CNS Vital Signs), with the standardized verbal memory score as the primary outcome. Secondary outcomes included other cognitive domains and plasma brain-derived neurotrophic factor (BDNF) levels. Safety was evaluated through adverse event monitoring and clinical assessments. Results: Sixty-six participants were included in the analysis. After 12 weeks, standardized verbal memory scores were significantly higher in the sPls group than in the placebo group (estimated marginal mean difference, 10.1; 95% confidence interval, 0.4-19.9; Conclusion: In cognitively healthy middle-aged and older adults with below-average verbal memory, 12 weeks of sPls supplementation was associated with improved verbal memory compared with placebo. Exploratory analyses also suggested potential improvements in selected attention-related cognitive domains. Dietary sPls may have the potential to support cognitive function in this population; however, further studies are required to confirm these findings and evaluate long-term safety. Clinical trial registration: https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000066286, identifier UMIN000057985.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.